These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279 [TBL] [Abstract][Full Text] [Related]
23. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters]. Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599 [TBL] [Abstract][Full Text] [Related]
24. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Davidson B; Shafat I; Risberg B; Ilan N; Trope' CG; Vlodavsky I; Reich R Gynecol Oncol; 2007 Feb; 104(2):311-9. PubMed ID: 17030350 [TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance. Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742 [TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282 [TBL] [Abstract][Full Text] [Related]
28. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Elstrand MB; Kleinberg L; Kohn EC; Tropé CG; Davidson B Int J Gynecol Pathol; 2009 May; 28(3):211-21. PubMed ID: 19620938 [TBL] [Abstract][Full Text] [Related]
29. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598 [TBL] [Abstract][Full Text] [Related]
30. Expression of CD44 alternative splicing variants in primary and lymph node metastatic lesions of gynecological cancer. Yorishima T; Nagai N; Ohama K Hiroshima J Med Sci; 1997 Mar; 46(1):21-9. PubMed ID: 9114564 [TBL] [Abstract][Full Text] [Related]
32. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246 [TBL] [Abstract][Full Text] [Related]
33. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Roland IH; Yang WL; Yang DH; Daly MB; Ozols RF; Hamilton TC; Lynch HT; Godwin AK; Xu XX Cancer; 2003 Dec; 98(12):2607-23. PubMed ID: 14669280 [TBL] [Abstract][Full Text] [Related]
34. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113 [TBL] [Abstract][Full Text] [Related]
35. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Davidson B; Reich R; Goldberg I; Gotlieb WH; Kopolovic J; Berner A; Ben-Baruch G; Bryne M; Nesland JM Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247 [TBL] [Abstract][Full Text] [Related]
36. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402 [TBL] [Abstract][Full Text] [Related]
37. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Davidson B; Baekelandt M; Shih IeM Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338 [TBL] [Abstract][Full Text] [Related]
38. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Ross JS; Sheehan CE; Williams SS; Malfetano JH; Szyfelbein WM; Kallakury BV Am J Clin Pathol; 2001 Jul; 116(1):122-8. PubMed ID: 11447742 [TBL] [Abstract][Full Text] [Related]
39. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Kmet LM; Cook LS; Magliocco AM Cancer; 2003 Jan; 97(2):389-404. PubMed ID: 12518363 [TBL] [Abstract][Full Text] [Related]
40. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Nguyen VN; Mirejovský T; Melinová L; Mandys V Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]